Biocopy presents "ValidaTe" – A novel ultra-fast screening technology

ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

BioCopy AG introduces **ValidaTe**, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates for T-cell therapy. ValidaTe is now available to biopharmaceutical companies.

With **ValidaTe**, about 5,000 protein-protein binding interactions are characterized simultaneously in one hour on one chip. Thus, **ValidaTe** chips can mirror the complexity of the human immune system. Drug candidates can be identified and drug leads can be validated instantly by screening thousands of peptide-HLA complexes placed on a thumbnail-sized surface. This parallel measurement of binding interactions is based on a proprietary label-free detection technology, which delivers highly accurate and detailed time-resolved kinetic data sets.

ValidaTe significantly shortens the time-consuming and laborious drug discovery and validation phase for novel T-cell therapies. It can provide a decisive head start in drug development, setting new benchmarks for speed and efficiency.

With this ground-breaking technology, biopharmaceutical companies can characterize and validate the efficacy and safety of T-cell drug candidates within days instead of months. The ValidaTe array can be tailored to measure the active structures of individual drug candidates for T-cell therapeutics, such as TCR-bispecifics or TCR-T-cells.

Product enhancements in 2022 include an expanded array capacity of 10,000 spots and cell-based formats.

Press release

29-Mar-2022
Source: BioCopy AG

Further information

- BioCopy AG